@entity1091 and the developing XXXX kidney in transplacental target organ @entity137 .

@entity2011 @entity137 @entity8 @entity851 @entity3486 @entity35 @entity1091
Pregnant female albino @entity35 were treated orally with @entity3486 dissolved in distilled water. Treatment at 100 mg/kg day 16 until day 20 of gestation caused marked maternal @entity137 including @entity2011 . For the progeny increased rates of prenatal and postnatal mortality were noted. In part of the progeny sacrificed near term by Caesarean section, the visceral examination of the fetuses revealed an enlargement of the renal pelves in association with rudimentary or missing papillae. The @entity8 are interpreted as being consistent with a @entity851 due to specific @entity1091 activity. After birth, i.e. after termination of maternal treatment, slight to moderate structural changes of the kidney were apparently compensated. 60 mg/kg through days 16-20 of pregnancy caused moderate maternal @entity137 including @entity2011 . The offspring showed a postnatal development near the normal range, however, and no @entity8 were recorded. In the view of the nephrotrophic property of @entity1091 as known for the adult @entity35 , the results indicate that possible transplacental effects on the fetal kidney as a target organ should be also considered.
